WVU OFFERS NEW CLINICAL TRIALS ON PROMISING LUNG CANCER DRUG
Posted on 4/8/2013
HSC 2020 Strategic Plan Priority: Raise the health status of West Virginians
MORGANTOWN, W.Va. – The Mary Babb Randolph Cancer Center at West Virginia University is participating in two national research studies to test a promising new drug that could benefit lung cancer patients with advanced or metastatic lung cancer.
The purpose of the studies is to see how the drug, BMS-936558, compares to docetaxel, a standard chemotherapy used as second-line treatment for patients who have been previously treated for advanced or metastatic squamous cell non-small cell lung cancer or previously treated metastatic non-squamous non-small cell lung cancer.
“Preliminary data on BMS-936558 presented at national meetings showed some promising results,” Mohammed Almubarak, M.D., of the Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program at the WVU Cancer Center, said. “The early results are exciting because they offer patients an alternative to conventional second-line treatments like docetaxel.”